Bernstein Reinstates Outperform on Guardant Health, Announces $175 Price Target

Benzinga Newsdesk www.benzinga.com Positive 77.3%

Neg 0% Neu 0% Pos 77.3%

Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and announces $175 price target.